JITC Logo

About JITC

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.

Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.

The quality of the journal could not be sustained without the efforts of our dedicated reviewers.

Become a Reviewer

Help enrich communication and advance scientific understanding in cancer immunotherapy.

For Authors

JITC's distinguished Editorial Board highlights featured content from the journal and beyond.

From the Editors

Readers have the opportunity to view JITC's special editions and theme-focused collections.

JITC Collections

Get to Know JITC's Leadership

JITC is pleased to welcome Michael T. Lotze, MD as the journal's new Editor-in-Chief. He is working with Interim Editor-in-Chief, James L. Gulley, MD, PhD, FACP, throughout 2024 as leadership is transferred. In addition, Sjoerd H. van der Burg, PhD has been promoted to Deputy Editor-in-Chief after a tremendous year of support in an interim capacity in 2023. Read more about this phenomenal group of leaders.

Get the chance to meet these editors at conferences throughout the year. From Barcelona, Spain to San Diego, CA, our editors will be available to meet with you and learn about your research. Check back for more information on Meet-the-Editor opportunities in 2024.

JITC Awards

Together with SITC, the journal recognizes key contributors to the journal and field of cancer immunotherapy, both in leadership and in research.

Annual JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts.

The Pedro J. Romero, MD Service to JITC Award recognizes an individual who has made significant contributions and demonstrated outstanding commitment to the journal.

APC Discounts

As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 35 percent discount on Article Processing Charges (APCs) for all accepted JITC articles submitted in 2024. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.

JITC also offers full waivers for the full APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission.

For additional information regarding these discounts, as well as institutional arrangements and editor/reviewer discounts, view the journal's APC policy. Additional questions may be directed to JITCEditor@sitcancer.org.

Highly Accessed Articles

What is the article Altmetric Attention Score?

Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes

Noam Levin, Sanghyun P Kim, Charles A Marquardt, Nolan R Vale, Zhiya Yu, Sivasish Sindiri, Jared J Gartner, Maria Parkhurst, Sri Krishna, Frank J Lowery, Nikolaos Zacharakis, Lior Levy, Todd D Prickett, Tiffany Benzine, Satyajit Ray, Robert V Masi, Billel Gasmi, Yong Li, Rafiqul Islam, Alakesh Bera, Stephanie L Goff, Paul F Robbins and Steven A Rosenberg

CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs

Gan Xiong, Zhi Chen, Qianwen Liu, Fang Peng, Caihua Zhang, Maosheng Cheng, Rongsong Ling, Shuang Chen, Yu Liang, Demeng Chen and Qimin Zhou

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Renske M T ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John Haanen and Valesca P Retel

Browse the Current Issue

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma

yesterday

Background Autologous BCMA-specific CAR T-cell therapies have substantial activity in multiple myeloma (MM). However, due to logistical limitations and BCMAlow relapses, there is a need for alternatives. UCARTCS1 cells are off-the-shelf allogeneic CAR T-cells derived from healthy donors targeting SLAMF7 (CS1), which is highly expressed in MM cells...
ImmunoPET imaging of LAG-3 expression in tumor microenvironment with 68Ga-labelled cyclic peptides tracers: from bench to bedside

yesterday

Background Lymphocyte activation gene 3 (LAG-3) has been considered as the next generation of immune checkpoint and a promising prognostic biomarker of immunotherapy. As with programmed cell death protein-1/programmed death-ligand 1 and cytotoxic T-lymphocyte antigen-4 inhibitors, positron emission tomography (PET) imaging strategies could benefit...
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

yesterday

Background TG6050 was designed as an improved oncolytic vector, combining the intrinsic properties of vaccinia virus to selectively replicate in tumors with the tumor-restricted expression of recombinant immune effectors to modify the tumor immune phenotype. These properties might be of particular interest for "cold" tumors, either poorly infiltrated...
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy

yesterday

Background Androgen deprivation therapy (ADT) is a front-line treatment for prostate cancer. In some men, their tumors can become refractory leading to the development of castration-resistant prostate cancer (CRPC). This causes tumors to regrow and metastasize, despite ongoing treatment, and impacts negatively on patient survival. ADT is known to...
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling

yesterday

Background Over the past decade, cancer immunotherapies have revolutionized the treatment of melanoma; however, responses vary across patient populations. Recently, baseline tumor size has been identified as an independent prognostic factor for overall survival in patients with melanoma receiving immune checkpoint inhibitors. MG1 is a novel oncolytic...

About JITC

About JITC

The quality of the journal could not be sustained without the efforts of our dedicated reviewers.

Help enrich communication and advance scientific understanding in cancer immunotherapy.

JITC's distinguished Editorial Board highlights featured content from the journal and beyond.

Readers have the opportunity to view JITC's special editions and theme-focused collections.

Get to Know JITC's Leadership

JITC Awards

APC Discounts

Highly Accessed Articles

What is the article Altmetric Attention Score?

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes

CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Browse the Current Issue

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma

ImmunoPET imaging of LAG-3 expression in tumor microenvironment with 68Ga-labelled cyclic peptides tracers: from bench to bedside

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling

Membership Links

Get Involved